Inspire Medical Systems (INSP) FDA Approvals $43.36 -0.90 (-2.04%) Closing price 03:59 PM EasternExtended Trading$43.74 +0.38 (+0.88%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Inspire Medical Systems' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Inspire Medical Systems (INSP). Over the past two years, Inspire Medical Systems has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Inspire. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Inspire V FDA Regulatory Events Inspire V is a drug developed by Inspire Medical Systems for the following indication: for patients with obstructive sleep apnea (OSA). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Outcome - October 10,2025Outcome Drug: Inspire VAnnounced Date: October 10, 2025Indication: for patients with obstructive sleep apnea (OSA)AnnouncementInspire Medical Systems, Inc. today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company's limited market release in the United States including single site experience at two leading centers.AI SummaryInspire Medical Systems, Inc. published clinical outcomes for its new Inspire V system from a Singapore study and a limited U.S. market release at leading centers. In Singapore, 44 patients were followed for six months after implantation. Surgeons cut implant times by 20% compared to the previous model, and all procedures succeeded. Internal respiratory sensing removed the need for external leads, and the device achieved 87% inspiratory phase overlap versus 79% with the older system. Patients averaged 5.5 hours per night on therapy, and their average apnea-hypopnea index dropped from 34 to 8 events per hour. Safety was strong, with only two minor infections. In the U.S., 101 patients at ten centers completed implants without serious issues. At 60 days, patients used the device 6.8 hours nightly at 1.7 volts. Preliminary sleep studies on 34 patients showed AHI cut from 30 to 4.5 events per hour. Single-site data from Boston and Colorado confirm shorter procedure times and higher surgery volume.Read Announcement Inspire Medical Systems FDA Events - Frequently Asked Questions Has Inspire Medical Systems received FDA approval? As of now, Inspire Medical Systems (INSP) has not received any FDA approvals for its therapy in the last two years. What drugs has Inspire Medical Systems submitted to the FDA? In the past two years, Inspire Medical Systems (INSP) has reported FDA regulatory activity for Inspire V. What is the most recent FDA event for Inspire Medical Systems? The most recent FDA-related event for Inspire Medical Systems occurred on October 10, 2025, involving Inspire V. The update was categorized as "Outcome," with the company reporting: "Inspire Medical Systems, Inc. today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company's limited market release in the United States including single site experience at two leading centers." What conditions do Inspire Medical Systems' current drugs treat? Currently, Inspire Medical Systems has one therapy (Inspire V) targeting the following condition: for patients with obstructive sleep apnea (OSA). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Actuate Therapeutics FDA EventsAnixa Biosciences FDA EventsAlterity Therapeutics FDA EventsBridgeBio Pharma FDA EventsAlpha Tau Medical FDA EventsGalectin Therapeutics FDA EventsInhibrx Biosciences FDA EventsMBX Biosciences FDA EventsProQR Therapeutics FDA EventsZai Lab FDA Eventsargenex FDA EventsArtiva Biotherapeutics FDA EventsBiogen FDA EventsPlus Therapeutics FDA EventsVistaGen Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies TransMedics Group FDA Events Liquidia FDA Events MiniMed Group FDA Events Soleno Therapeutics FDA Events AxoGen FDA Events NovoCure FDA Events Artivion FDA Events Pulse Biosciences FDA Events PROCEPT BioRobotics FDA Events iRadimed FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NYSE:INSP last updated on 10/10/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inspire Medical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inspire Medical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outcome - October 10,2025Outcome Drug: Inspire VAnnounced Date: October 10, 2025Indication: for patients with obstructive sleep apnea (OSA)AnnouncementInspire Medical Systems, Inc. today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company's limited market release in the United States including single site experience at two leading centers.AI SummaryInspire Medical Systems, Inc. published clinical outcomes for its new Inspire V system from a Singapore study and a limited U.S. market release at leading centers. In Singapore, 44 patients were followed for six months after implantation. Surgeons cut implant times by 20% compared to the previous model, and all procedures succeeded. Internal respiratory sensing removed the need for external leads, and the device achieved 87% inspiratory phase overlap versus 79% with the older system. Patients averaged 5.5 hours per night on therapy, and their average apnea-hypopnea index dropped from 34 to 8 events per hour. Safety was strong, with only two minor infections. In the U.S., 101 patients at ten centers completed implants without serious issues. At 60 days, patients used the device 6.8 hours nightly at 1.7 volts. Preliminary sleep studies on 34 patients showed AHI cut from 30 to 4.5 events per hour. Single-site data from Boston and Colorado confirm shorter procedure times and higher surgery volume.Read Announcement
